Platinum제로 항암 치료한 진행성 비소세포폐암종 환자에서 HER-2/neu, ERCC1과 GST-pi에 대한 연구

참고문헌 (30)

1. Bai F, "Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma", Cancer, 78, pp.416~421 (1996)
2. Brundage MD, "Prognostic factors in nonsmall cell lung cancer: a decade of progress", Chest, 122, pp.1037~1057 (2002)
3. American Society of Clinical Oncology, "Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology", J Clin Oncol, 15, pp.2996~3018 (1997)
4. Moufarij MA, "Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines", Mol Pharmacol, 63, pp.862~869 (2003)
5. Bonomi P, "Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial", J Clin Oncol, 18, pp.623~631 (2000)
6. Sobin LH, "TNM classification of malignant tumors, fifth edition (1997)", Cancer, 80, pp.1803~1804 (1997)
7. Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", J Natl Cancer Inst, 92, pp.205~216 (2000)
8. Wachters FM, "ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III", IV NSCLC patients treated with chemotherapy, 2005, pp.50, 211~219
9. Tanner M, "Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2", neu oncogene amplification in archival breast cancer samples, 2000, pp.157, 1467~1472
10. Coussens L, "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene", Science, 230, pp.1132~1139 (1985)
11. Giatromanolaki A, "CerbB- 2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival", Anticancer Res, 20, pp.997~1004 (2000)
12. Hancock MC, "A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines", Cancer Res, 51, pp.4575~4580 (1991)
13. Makar AP, "The expression of c-erbB-2 (HER-2", neu) oncogene in invasive ovarian malignancies, 1994, pp.4, 194~199
14. Miyazono F, "Quantitative cerbB- 2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer", Br J Cancer, 91, pp.666~672 (2004)
15. Tateishi M, "Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma", Eur J Cancer, 27, pp.1372~1375 (1991)
16. Selvaggi G, "HER-2", neu overexpression in patients with radically resected nonsmall cell lung carcinoma: impact on long-term survival, 2002, pp.94, 2669~2674
17. Menard S, "Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables", J Clin Oncol, 19, pp.329~335 (2001)
18. Meden H, "Overexpression of the oncogene c-erbB-2 (HER2", neu) and response to chemo-therapy in patients with ovarian cancer, 1998, pp.17, 61~65
19. Zhang F, "Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma", Cancer, 97, pp.1758~1765 (2003)
20. Tsai CM, "Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2", neu gene expression but not with ras gene mutations, 1993, pp.85, 897~901
21. Tsai CM, "Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells", Cancer Res, 56, pp.1068~1074 (1996)
22. Greatens TM, "Do molecular markers predict survival in non-small-cell lung cancer?", Am J Respir Crit Care Med, 157, pp.1093~1097 (1998)
23. Tsai CM, "Enhanced chemoresistance by elevation of p185neu levels in HER-2", neu-transfected human lung cancer cells, 1995, pp.87, 682~684
24. Simon GR, "ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer", Chest, 127, pp.978~983 (2005)
25. Olaussen KA, "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy", N Engl J Med, 355, pp.983~991 (2006)
26. Lord RV, "Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer", Clin Cancer Res, 8, pp.2286~2291 (2002)
27. De Silva IU, "Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells", Mol Cell Biol, 20, pp.7980~7990 (2000)
28. Eimoto H, "Expression of the glutathione S-transferase placental form in human lung carcinomas", Carcinogenesis, 9, pp.2325~2327 (1988)
29. Miyazaki M, "Drug resistance to cis-diamminedichloroplatinum (II) in Chinese hamster ovary cell lines transfected with glutathione S-transferase pi gene", Biochem Biophys Res Commun, 166, pp.1358~1364 (1990)
30. Okuyama T, "Expression of glutathione Stransferase- pi and sensitivity of human gastric cancer cells to cisplatin", Cancer, 74, pp.1230~1236 (1994)

관련 논문AI추천